Loading...
Participants
Ernst R. Berndt, Massachusetts Institute of Technology and NBER
Gregory Bloss, National Institutes of Health
Cynthia Chen, University of Southern California
Karen Eggleston, Stanford University and NBER
Sara Geiger, University of Southern California
Dana Goldman, University of Southern California and NBER
Philippe Gorry, University of Bordeaux
John A. Graves, Vanderbilt University
Manuel Hermosilla, Johns Hopkins University
Jason Hockenberry, Yale University and NBER
David H. Howard, Emory University
Darius N. Lakdawalla, University of Southern California and NBER
Jorge A. Lemus, University of Illinois, Urbana-Champaign
Frank R. Lichtenberg, Columbia University and NBER
Jui-fen Rachel Lu, Chang Gung University, Taiwan
Betsy MacLeod, Columbia University
Lee Nunley, Columbia University
Mark Pauly, University of Pennsylvania and NBER
Rebecca A. Pulk, Geisinger Health System
John Rowe, Columbia University
Ariel Dora Stern, Harvard University
Mark Trusheim, Massachusetts Institute of Technology
Marc S. Williams, Geisinger Health System
Eric Wright, Geisinger Health System
Related
Programs
Papers
Cost Sharing in Insurance Coverage for Precision Medicine
Personalized Medicine When Physicians Induce Demand
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies.
The Value of Pharmacogenomic Information
The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory
Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments
Personalized Medicine When Physicians Induce Demand
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies.
The Value of Pharmacogenomic Information
The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory
Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments